Mirada Medical
Mirada Medical is an Oxford-based, privately held medical imaging software company that develops FDA-cleared AI-enabled image registration, auto-contouring, and dosimetry tools sold to hospitals, cancer centers, and OEM imaging partners for cancer diagnosis and radiotherapy planning.
- Company typePrivate
- Founded1999
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Mirada Medical does
Mirada Medical is an Oxford-headquartered medical imaging software company founded in 1999 that develops AI-enabled image registration, quantification, and treatment planning tools used in cancer diagnosis and therapy. Its product portfolio spans three specialty areas: Mirada XD for diagnostic PET/CT, PET/MR, and nuclear medicine reading; Mirada RTx and DLCExpert for radiation oncology image registration and AI-driven organ-at-risk auto-contouring (the first FDA-cleared AI of its kind globally); and Simplicit90Y for dosimetry planning in Y-90 selective internal radiation therapy. The technology stack combines deep learning-based contouring models, the proprietary RegEngine deformable image registration engine developed over more than 20 years, and a zero-click automation platform designed to plug directly into existing PACS and treatment planning systems.
Mirada generates revenue primarily through annual enterprise software licensing to hospitals and cancer centers, supplemented by OEM/embedded licensing royalties from major imaging and radiotherapy vendors (GE Healthcare, Canon, Philips, Varian, Boston Scientific) that distribute Mirada's technology within their own platforms. Distribution combines direct enterprise field sales in the UK and US with channel partnerships that broaden reach to over 2,000 hospitals globally. The company has secured two NHS AI in Health and Care Awards and a 2024 Innovate UK precision medicine grant, reflecting UK public-sector validation of its clinical evidence base.
The business is privately held and backed by healthcare-focused private equity firm Apposite Capital, which has invested approximately $20 million of growth capital since 2019 and holds a board seat. Mirada operates from Oxford, Denver, and Bordeaux, with a headcount in the 51-100 range. Recent strategic emphasis has shifted toward commercial scaling under a new CEO (Dr Karen Fitchett, 2024) and a newly appointed VP of Revenue, alongside expansion into PSMA PET/CT AI for prostate cancer and Dosimetry-as-a-Service offerings through the TeleDaas PLLC partnership.
Mirada Medical firmographics
Firmographics- Name
- Mirada Medical
- Legal name
- Mirada Medical Limited
- Website
- https://mirada-medical.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Mirada Medical is an Oxford-based, privately held medical imaging software company that develops FDA-cleared AI-enabled image registration, auto-contouring, and dosimetry tools sold to hospitals, cancer centers, and OEM imaging partners for cancer diagnosis and radiotherapy planning.
- Ownership category
- akta.pro rank
Mirada Medical industry classification
Industry- Product category
- Medical Imaging Software
- NAICS
- Software Publishers (5132), Software Publishers (51321)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industries
- Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ), Radiology Reporting, Dictation & Structured Reporting (HLACALAF), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
Keywords
Where Mirada Medical is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Mirada Medical business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Medical Imaging Software Licenses: Mirada Medical generates revenue primarily through licensing its medical imaging software products including Mirada XD, Mirada RTx, DLCExpert, and Simplicit90Y. Products are sold directly to hospitals and through OEM partners who embed Mirada technology in their platforms.
- OEM/Embedded Software Licensing: Mirada provides its technology on an OEM basis to leading healthcare companies including GE, Canon, Philips, Varian, and Boston Scientific. These partnerships embed Mirada's software within partner platforms, generating licensing revenue.
- Professional Services and Support: The company provides customer success services including clinical onboarding, in-clinic deployment, and ongoing optimization support. Implementation and training services are part of the customer engagement model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise hospital licensing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Mirada Medical product offering
Product offeringCore offering
Mirada Medical develops and licenses AI-powered medical imaging software for cancer care across three clinical specialties: diagnostic imaging (Mirada XD for PET/CT, PET/MR, and nuclear medicine reading), radiation oncology (Mirada RTx for image registration and visualization, DLCExpert for AI-powered organ-at-risk autocontouring), and interventional radiology (Simplicit90Y for Y-90 SIRT dosimetry planning). Products are sold directly to hospitals and cancer centers and embedded through OEM partnerships with GE Healthcare, Canon, Philips, Varian, and Boston Scientific.
Product overview
Mirada Medical delivers a unified portfolio of medical imaging software for diagnosis, dosimetry, and image-guided cancer therapy across three specialties: diagnostic imaging, radiation oncology, and interventional radiology. The core product families are Mirada XD (diagnostic imaging software for PET/CT, PET/MR, and nuclear medicine reading), Mirada RTx (radiation oncology image registration and visualization platform), and Simplicit90Y (interventional dosimetry software for Y-90 SIRT). Key AI capabilities include DLCExpert for automated organ-at-risk contouring, RegEngine for deformable image registration, and zero-click automation platforms. Products are available under Mirada's own brand and on an OEM basis through partnerships with GE, Canon, Philips, Boston Scientific, Varian, and other leading healthcare companies. The software integrates with DICOM-compatible systems and PACS infrastructure across thousands of hospitals globally.
Differentiator
Problem solved
Functional benefit
Brands
- Mirada XD: Integrated vendor-neutral software for diagnostic reading of PET/CT, PET/MR, nuclear medicine, and image fusion.
- Mirada RTx
- Simplicit90Y
- DLCExpert
- RegEngine
Products and services
- Mirada XD
Quantifiable outcome
- 40-60% reduction in contouring time for H&N, breast, and pelvic disease sites
- +4 more outcomes
Companies that use Mirada Medical
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles1 record
Mirada Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability9 records
Feature6 records
Mirada Medical partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered strategic, core and minor.
- Leeds Teaching Hospitals NHS TruststrategicClinical partner for £500,000 Innovate UK grant to develop AI-assisted PSMA PET/CT solution for improved prostate cancer diagnosis.
- Newcastle upon Tyne Hospitals NHS Foundation TruststrategicClinical partner collaborating on PSMA PET/CT AI solution development under Innovate UK Advancing Precision Medicine grant.
- University Hospitals Bristol and Weston NHS Foundation TruststrategicClinical partner for PSMA PET/CT AI-assisted solution research and development supporting widespread adoption of PSMA PET/CT in the clinic.
- TeleDaas PLLCstrategicDosimetry-as-a-Service medical practice using Mirada's proprietary software to support clinical research organizations in clinical trial design and development of new targeted radiation therapies.
- RefleXion MedicalstrategicNon-exclusive worldwide licensing agreement allowing integration of Mirada's RegEngine image registration algorithms into RefleXion X1 treatment planning software for biology-guided radiotherapy (BgRT).
- GE HealthcarecoreGlobal collaboration to improve outcomes for cancer patients by integrating Mirada's advanced automation and AI technologies to enable faster, more consistent and more precise cancer radiotherapy treatment. Mirada technology embedded in GE Healthcare ecosystem.
- Boston ScientificcorePartnership to develop and commercialize Simplicit90Y, a software product enabling personalization of dosimetry planning for TheraSphere, Boston Scientific's radiation-based cancer treatment using microscopic radioactive glass microspheres.
- Canon Medical SystemscoreMirada Oncology Fusion product offered through Canon, integrating Mirada's imaging software with Canon's healthcare IT platform for clinical applications.
- PhilipscorePartnership integrating Mirada's imaging technology within Philips healthcare solutions. Mirada products available through Philips ecosystem for diagnostic imaging.
- VariancoreMirada technology available through Varian's radiotherapy platform, enhancing treatment planning capabilities with Mirada's image registration and AI contouring.
- Change HealthcareminorDistribution partnership making Mirada technology available through Change Healthcare's imaging solutions and customer network.
- NCIMI (National Consortium of Intelligent Medical Imaging)strategicCollaboration with Leeds Teaching Hospitals and Alliance Medical Group investigating role of AI and Deep Learning in diagnostic nuclear medicine, particularly for lymphoma detection and reporting.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Mirada Medical competitors and assessment
Company assessmentDirect peers
- RaySearch Laboratories: Swedish developer of radiation therapy treatment planning software (RayStation) and oncology analytics. Direct competitor to Mirada RTx and DLCExpert, serving the same radiation oncology customer base with overlapping image registration and adaptive planning capabilities.
- MIM Software: US-based medical imaging software vendor offering multi-modality viewing, deformable registration, and AI-driven contouring (MIM Maestro). Closely comparable to Mirada's diagnostic imaging and radiation oncology workflows and customer base.
- Brainlab: Private German company providing treatment planning, image-guided surgery and radiotherapy software (Elements). Directly competes with Mirada in radiation oncology planning and image registration, with overlapping hospital and cancer center customers.
Broad incumbents
- Elekta: Swedish listed vendor of linear accelerators and radiotherapy software (Mosaiq, Elekta ONE). A broader incumbent in radiation oncology that competes with and could substitute Mirada's planning and autocontouring capabilities as part of its integrated portfolio.
- Varian (a Siemens Healthineers company): Global leader in radiation oncology treatment planning (Eclipse) and Ethos adaptive radiotherapy. Both an OEM partner of Mirada (Varian) and a potential substitute supplier, making it a strategic incumbent in the same category.
- Accuray: US-listed developer of CyberKnife and TomoTherapy radiation therapy systems with associated planning software. Broader incumbent serving overlapping radiation oncology customers and competing for the same hospital capital budgets.
Emerging players
- RefleXion Medical: US-based developer of biology-guided radiotherapy (BgRT) systems that licenses Mirada's RegEngine for its X1 platform. Emerging player in adaptive radiotherapy with a partial, partnership-based overlap to Mirada's image registration business.
- Quibim: Spanish AI imaging analytics company offering quantitative imaging biomarkers for oncology and radiology. Emerging AI-native vendor addressing similar PET/CT, MRI, and oncology quantification workflows as Mirada XD.
Others
- GE HealthCare: Global medical imaging equipment and healthcare IT vendor and an OEM partner of Mirada. Adjacent incumbent that both distributes Mirada's technology and develops its own AI imaging applications, making it a strategically dual customer-competitor.
- Philips: Global healthcare technology vendor with diagnostic imaging, PACS, and oncology informatics offerings, and an OEM partner embedding Mirada's technology. Comparable as a broad incumbent and channel partner rather than a direct specialist competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Mirada Medical social profiles
Digital presenceMirada Medical compliance and trust
Trust signalCompliance3 records
Mirada Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirada Medical leadership team
Management profileNumber of profiles
Profiles6 records
Mirada Medical funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirada Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirada Medical
What does Mirada Medical do?
Mirada Medical develops and licenses AI-powered medical imaging software for cancer care across three clinical specialties: diagnostic imaging (Mirada XD for PET/CT, PET/MR, and nuclear medicine reading), radiation oncology (Mirada RTx for image registration and visualization, DLCExpert for AI-powered organ-at-risk autocontouring), and interventional radiology (Simplicit90Y for Y-90 SIRT dosimetry planning). Products are sold directly to hospitals and cancer centers and embedded through OEM partnerships with GE Healthcare, Canon, Philips, Varian, and Boston Scientific.
Is Mirada Medical a public or private company?
Mirada Medical is a private company. It is classified as private equity controlled and is currently operating.
When was Mirada Medical founded?
Mirada Medical was founded in 1999. It employs 51 to 100 people.
Where is Mirada Medical based?
Mirada Medical is headquartered in Oxford, United Kingdom, in the Europe region.
How does Mirada Medical make money?
Three revenue lines are on record. Medical Imaging Software Licenses are the primary driver. The others are OEM/Embedded Software Licensing and professional Services and Support.
Who are Mirada Medical's main competitors?
Direct peers on record are RaySearch Laboratories, MIM Software and Brainlab. Broad incumbents are Elekta, Varian (a Siemens Healthineers company) and Accuray. Emerging players are RefleXion Medical and Quibim. Others are GE HealthCare and Philips.
Does Mirada Medical have an API?
No public API is recorded for Mirada Medical.
What industry is Mirada Medical in?
Mirada Medical's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACALAD, Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic). Its NAICS code is 5132 and its SIC code is 3841.